ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)’s share price rose 7.9% during mid-day trading on Tuesday . The company traded as high as $0.60 and last traded at $0.50. Approximately 792,900 shares were traded during mid-day trading, an increase of 32% from the average daily volume of 602,651 shares. The stock had previously closed at $0.54.
Separately, Maxim Group reiterated a “buy” rating and issued a $4.00 price target on shares of ContraVir Pharmaceuticals in a research note on Thursday, August 24th.
The stock has a 50-day moving average price of $0.56 and a 200 day moving average price of $0.90. The stock’s market cap is $31.75 million.
A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. raised its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after purchasing an additional 366,192 shares during the period. Vanguard Group Inc. owned 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.28% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/2887169/contravir-pharmaceuticals-inc-ctrv-stock-price-up-7-9.html.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.